05.07.24 -- CGT: An Overview Of FDA Regulatory Considerations For 2024

What enabled the evolution of TIL therapies? What does the future hold for them? And where should you concentrate your efforts to accelerate progress? Watch for answers to these questions and more.

Ensure a stable and reliable supply of essential medications for patients by proactively tackling pharmaceutical supply chain challenges and embracing innovative risk management strategies.

Learn why failure to include at least some elements of GMP in your cell line design and development process could make it more difficult to get the data required for future IND or BLAs.

Here, we introduce an optimized workflow for analyzing rare antigen-specific T cells from human blood and PBMCs and address critical challenges.

Explore operational technology vulnerability assessment findings that may be unexpected or unanticipated, answers to questions about OT vulnerability assessments and pentesting, and more.

Discover a more human-relevant platform that enables researchers to assess the trafficking and killing efficiency of immunotherapy as well as the proof-of-concept of immuno-oncology co-therapy.

Evaluate the performance of a single-use centrifuge biopharmaceutical organizations can utilize in the clarification of Expi293F cells through its measuring of supernatant turbidity and viable cell recovery.

A growing number of AAV product developers are recognizing the value in moving to suspension as early in development as possible in order to optimize production.

Investigate important considerations for working with three different stem cell types: mesenchymal stem/stromal cells, induced pluripotent stem cells, and neural stem cells.

In this study, synthetic acute myeloid leukemia (AML) mimic technology was deployed to tackle the AML control challenges faced by a leading global pharmaceutical company.